



BRAWN

03rd November 2018

To,

**BSE Limited,
Floor 25, Phirozee Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400001**



4EAA5

CIN NO.: L74899DL1985PLC022468

Sub: Outcome of 3rd/ 2018- 19 Board Meeting and Submission of Un-audited Financial Results for the quarter and half year ended 30.09.2018
Scrip Code: 530207

Dear Sir,

This is to inform you that the 3rd/ 2018-19 meeting of the Board of Directors held today i.e., Saturday, 03rd November, 2018, commenced at 02:00 P.M and concluded at 03:30 P.M, at the Registered Office of the Company situated at 4B, Asaf Ali Road, II Floor, Delhi Stock Exchange Building, New Delhi 110002, inter alia considered the following:

1. Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, approved the Un- audited Financial Results for quarter and half year ended 30th September, 2018. Copy of the results is enclosed herewith as Annexure- I.
2. Limited Review Report on Un- audited Financial Results for the quarter and half- year ended on 30th September, 2018 obtained from the Statutory Auditor has also been taken on record and copy of the same is enclosed herewith as Annexure- II.

You are requested to take above on record.

Thanking you,

For BRAWN BIOTECH LIMITED

Mamta
Mamta Surkali
Company Secretary

Encl: As above

BRAWN BIOTECH LTD.

(Formerly Known as Brawn Pharmaceuticals Ltd.)

... for better life

Regd. Office : 4B, Asaf Ali Road, II Floor, Delhi Stock Exchange Building, New Delhi 110002 IN Tel: 0124-4666152, 4222462,
Email: solution@brawnbiotech.com, Website : www.brawnbiotech.com

Export Office : 4B, Asaf Ali Road, II Floor, Delhi Stock Exchange Building, New Delhi 110002 IN Tel: 011-23275208 Fax : 011-23275208

Corporate Office : Plot No. - 30, Sector - 33 , Near Hero Honda Factory, Gurugram (Haryana) 122001 , Tel.: 0124-4666152, 4222462
Email: solution@brawnbiotech.com

Works : 13, Industrial Area, N.I.T., Faridabad -121001 (Haryana) Tel.: +91 - 8010416849/48



BRAWN

ANNEXURE - I
CIN NO.: L74899DL1985PLC022468

BRAWN BIOTECH LIMITED CIN:L74899DL1985PLC022468 REGD. OFFICE: 4B, Asaf Ali Road, II Floor, Delhi Stock Exchange Building, New Delhi 110002							
STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED ON SEPTEMBER 30, 2018							
Rs. In Lakhs							
Sr. No.	Particulars	Quarter ended			Half-yearly ended		Year ended
		3 months ended	3 months ended	3 months ended	6 months ended	6 months ended	Accounting Year ended
		30.09.2018	30.06.2018	30.09.2017	30.09.2018	30.09.2017	31.03.2018
		Un-audited	Un-audited	Un-audited	Un-audited	Un-audited	Audited
1	Revenue from operations						
	Revenue from operations	1,495.91	1,356.19	1,159.52	2,852.09	2,253.85	5,578.37
	Other Income	7.83	6.12	18.04	13.95	33.98	8.97
	Total Revenue	1,503.73	1,362.31	1,177.56	2,866.04	2,287.83	5,587.34
2	Expenses						
a	Cost of material consumed	-	-	-	-	-	-
b	Purchase of stock-in-trade	1,347.14	1,192.23	988.81	2,539.38	1986.27	4882.19
c	Change in inventories of finished goods, work in progress and stock in trade	(7.75)	7.11	10.01	(0.65)	7.42	2.46
d	Employee Benefit expenses	54.98	57.71	56.43	112.70	108.02	298.19
e	Depreciation and amortisation expenses	0.81	0.80	0.80	1.60	1.58	3.16
f	Finance Cost	1.14	0.65	0.55	1.80	1.07	5.73
g	Other expenses	52.45	50.68	36.22	103.13	73.24	199.50
	Total Expenses	1,448.77	1,309.18	1,092.82	2,757.95	2,177.60	5,391.23
3	Profit from Operation before Other Income, exceptional and extraordinary items (1-2)	54.96	53.13	84.74	108.09	110.23	196.11
4	Other Income	-	-	-	-	-	-
5	Profit from ordinary activities before exceptional items (3-4)	54.96	53.13	84.74	108.09	110.23	196.11
6	Exceptional Items	-	-	-	-	-	-
7	Profit from ordinary activities before tax (5-6)	54.96	53.13	84.74	108.09	110.23	196.11
8	Tax Expenses	15.65	15.84	27.96	31.49	36.68	67.94
9	Profit (Loss) for the period from continuing operations (7-8)	39.31	37.29	56.78	76.59	73.55	128.17
10	Profit/(loss) from discontinuing operations	-	-	-	-	-	-
11	Tax expense of discontinuing operations	-	-	-	-	-	-
12	Profit/(loss) from Discontinuing operations (after tax) (10-11)	-	-	-	-	-	-
13	Profit (Loss) for the period (9+12)	39.31	37.29	56.78	76.59	73.55	128.17
14	Other Comprehensive Income	1.31	3.82	0.33	5.13	0.20	(2.74)
	Total Comprehensive Income	40.62	41.11	57.11	81.72	73.75	125.43
15	Details of equity share capital						
	Paid-up equity share capital	300.03	300.03	300.03	300.03	300.03	300.03
	Face value of equity share capital						
16	Reserve excluding Revaluation Reserve						463.06
17	Earnings per share						
i	Basic earnings per share	1.35	1.37	1.90	2.72	2.46	4.18
ii	Diluted earnings per share	1.35	1.37	1.90	2.72	2.46	4.18

NOTES :-

- Results for the quarter and half year ended on 30th September, 2018 were reviewed by the Audit committee and then approved by the Board of Directors at their meeting held on 03rd November, 2018.
- Statutory auditors have carried out the limited review of the financial results for the quarter and half year ended on 30.09.2018
- The above results have been prepared in compliance with the recognition and measurement principles of the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), as amended by the Companies (Indian Accounting Standards) (Amendment rules), 2016 prescribed under Section 133 of the companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.
- The Company is engaged primarily in the business of Pharmaceuticals. Accordingly, there is no separate reportable segments as per Ind-AS 108 dealing with Operating Segments.
- The above Standalone Un-audited Financial Results for the quarter and half year ended on 30.09.2018 are available on company's website www.brawnbiotech.com and BSE website www.bseindia.com.
- Previous year / period figures have been regrouped / rearranged, wherever necessary to make them comparable with the current period figures.

For and on behalf of Board
For Brawn Biotech Limited

Brj Raj Gupta
Managing Director
DIN NO. 00974968
Date : 03-11-2018
Place: Delhi

BRAWN BIOTECH LTD.

(Formerly Known as Brawn Pharmaceuticals Ltd.)

Regd. Office : 4B, Asaf Ali Road, II Floor, Delhi Stock Exchange Building, New Delhi 110002 IN Tel: 0124-4666152, 4222462,
Email: solution@brawnbiotech.com, Website : www.brawnbiotech.com

Export Office : 4B, Asaf Ali Road, II Floor, Delhi Stock Exchange Building, New Delhi 110002 IN Tel: 011-23275208 Fax : 011-23275208

Corporate Office : Plot No. - 30, Sector - 33 , Near Hero Honda Factory, Gurugram (Haryana) 122001 , Tel.: 0124-4666152, 4222462
Email: solution@brawnbiotech.com

Works : 13, Industrial Area, N.I.T., Faridabad -121001 (Haryana) Tel.: +91 - 8010416849/48

...for better life



BRAWN BIOTECH LIMITED
CIN:L74899DL1985PLC022468
Registered Office: 4B, Asaf Ali Road, II Floor, Delhi Stock Exchange Building, New Delhi 110002

Statement of Assets and Liabilities as on 30th September, 2018		
Particulars	Standalone	
	AS ON 30.09.2018 Un-audited Rupees in Lakhs	AS ON 31.03.2018 Audited Rupees in Lakhs
ASSETS		
Non-current assets		
(a) Property, Plant and Equipment	20.76	22.28
(b) Intangible Assets	-	-
(c) Financial Assets:		
(i) Trade Receivable	-	47.66
(ii) Loans	-	3.14
(e) Deferred tax assets (net)	8.00	8.00
(f) Other non-current assets	-	-
Sub Total Non Current Assets	28.76	81.08
Current assets		
(a) Inventories	35.41	34.76
(b) Financial Assets:		
(i) Trade receivables	1,948.24	1,505.42
(ii) Cash and cash equivalents	61.23	39.61
(iii) Bank balance other than (ii) above	-	-
(c) Other current financial assets	16.80	12.65
(d) Current Tax Assets(Net)	131.86	109.86
(e) Other Current Assets	230.36	473.85
Sub Total Current Assets	2,423.90	2,176.15
Total Assets	2,452.66	2,257.23
EQUITY AND LIABILITIES		
Equity		
(a) Share capital	300.03	300.03
(b) Other Equity	508.57	463.07
Total- Equity	808.60	763.10
Liabilities		
Non Current liabilities		
(a) Financial Liabilities		
(i) Trade Payable	-	3.32
(ii) other financial liabilities	31.50	-
(b) Provisions	-	16.72
(c) Deferred tax liabilities (net)	-	-
Total Non Current Liabilities	31.50	20.05
Current Liabilities		
(a) Financial Liabilities		
(i) Borrowings	-	-
(ii) Trade Payables	1,234.43	1,122.85
(b) other current financial liabilities	46.41	112.78
(c) Other Current Liability	188.88	83.16
(d) provisions	-	43.95
(d) current tax liabilities (net)	142.84	111.34
Total Current Liabilities	1,612.55	1,474.08
Total Equity and Liabilities	2,452.66	2,257.23

For and on behalf of Board
For Brawn Biotech Limited

(Signature)
NEW DELHI
110002
Brij Raj Gupta
Managing Director
DIN NO. 00974969
Place: New Delhi
Date: 03-11-2018

BRAWN BIOTECH LTD.

(Formerly Known as Brawn Pharmaceuticals Ltd.)

...for better life

Regd. Office : 4B, Asaf Ali Road, II Floor, Delhi Stock Exchange Building, New Delhi 110002 IN Tel: 0124-4666152, 4222462,
Email: solution@brawnbiotech.com, Website : www.brawnbiotech.com

Export Office : 4B, Asaf Ali Road, II Floor, Delhi Stock Exchange Building, New Delhi 110002 IN Tel: 011-23275208 Fax : 011-23275208

Corporate Office : Plot No. - 30, Sector - 33 , Near Hero Honda Factory, Gurugram (Haryana) 122001 , Tel.: 0124-4666152, 4222462
Email: solution@brawnbiotech.com

Works : 13, Industrial Area, N.I.T., Faridabad -121001 (Haryana) Tel.: +91 - 8010416849/48



Independent Auditor's Report on Quarterly Standalone Financial Results of BRAWN BIOTECH LIMITED pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To,
The Board of Directors of
Brawn Biotech Limited

We have reviewed the accompanying statement of Unaudited Financial Results of **Brawn Biotech Limited** (the "Company") for the quarter ended 30th September 2018 and the year to date results for the period 1st April 2018 to 30th September 2018, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No.CIR/CFD/FAC/62/2016 dated July 5, 2016. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial results based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards i.e., Ind AS prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No.CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Rajiv Udai & Associates
Chartered Accountants
Firm Registration No. 18764N


Rajeev Jain
(Partner)
(Membership No. 99767)



Place: Delhi
Date: 03-11-2018